BRCA+   

Questions discussed in this category



Definitions for "high risk" differ by whether patients receive neoadjuvant chemo and across other contemporary studies. Does the change in AJCC stagin...

In subset analyses of OlympiA there seems to be smaller magnitude of benefit among HR+ patients. In your opinion, should adjuvant olabarib be offered ...

Does your practice vary based on risk status (low vs high risk) or specific mutation status (BRCA+ vs HRD+) given PAOLA subset analyses? 

Is MDS/AML risk increased with longer duration of therapy? Does your approach differ for patients who are BRCA+/HRD vs wild type/HRP?


Papers discussed in this category


The New England journal of medicine, 2018-12-27

Lancet Oncol, 2021 Mar 18

N Engl J Med, 2019 Dec 19

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-09-10

Lancet Oncol, 2015 Jun 23

J Clin Oncol, 2020 Oct 29

N Engl J Med, 2021 Jun 03

N. Engl. J. Med.,

N. Engl. J. Med., 2017 Jun 04

Annals of oncology : official journal of the European Society for Medical Oncology, 2019-04-01

BMC Cancer, 2018 Mar 07

N Engl J Med,

JCO Oncol Pract, 2022 Jan 07

Lancet Oncol, 2020 Aug 27

The New England journal of medicine, 2018-08-23

N. Engl. J. Med.,

Lancet Oncol, 2020 Aug 06

The Lancet. Oncology, 2018-04

JAMA Oncol,

Mol Cell Endocrinol, 2021 Jan 26

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-05-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-01-10

The New England journal of medicine, 2018-07-12

Annals of Oncology, 2021 Sep 29

J. Clin. Oncol., 2020 Sep 20

J Clin Oncol, 2021 Aug 03

Breast Cancer Res Treat, 2016 Feb 18

Mol Cancer Ther, 2018 Mar 28

Eur J Cancer, 2014 Aug 12